Novel anti-obesity drugs and plasma lipids

References

• WHO. Obesity and overweight (2013). www.who.int/mediacentre/factsheets/fs311/en/index.html
   Google Scholar
• Shamseddeen H, Getty JZ, Hamdallah IN, Ali MR. Epidemiology and economic impact of obesity and Type 2 diabetes. Surg. Clin. North Am. 91(6), 1163–1172, vii (2011).
   Google Scholar
• Kyriazis I, Rekleiti M, Saridi M et al. Prevalence of obesity in children aged 6-12 years in Greece: nutritional behaviour and physical activity. Arch. Med. Sci. 9(5), 859–864 (2012).
   Google Scholar
• Haslam DW, James WP. Obesity. Lancet 366(9492), 1197–1209 (2005).
   Google Scholar
• Aguilera CM, Gil-Campos M, Canete R, Gil A. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin. Sci. (Lond.) 114(3), 183–193 (2008). • Interesting review evaluating alterations in plasma and tissue lipids associated with obesity.
   Google Scholar
• Li JJ, Wang H, Tino JA et al. 2-hydroxy-Narylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg. Med. Chem. Lett. 17(11), 3208–3211 (2007).
   Google Scholar
• Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther. 117(2), 207–231 (2008).
   Google Scholar
• Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr. Vasc. Pharmacol. 8(6), 820–830 (2010).
   Google Scholar
• Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Curr. Pharm. Des. 17(33), 3608–3610 (2011).
   Google Scholar
• Rizzo M, Kotur-Stevuljevic J, Berneis K et al. Atherogenic dyslipidemia and oxidative stress: a new look. Transl. Res. 153(5), 217–223 (2009).
   Google Scholar
• Mceneny J, Blair S, Woodside JV, Murray L, Boreham C, Young IS. High-density lipoprotein subfractions display proatherogenic properties in overweight and obese children. Pediatr. Res. 74(3), 279–283 (2013).
   Google Scholar
• Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res. 51(4), 314–324 (2012).
   Google Scholar
• Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am. J. Clin. Nutr. 83(2), 461S–465S (2006).
   Google Scholar
• Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Varady KA. Alternate day fasting and endurance exercise combine to reduce body weight and favorably alter plasma lipids in obese humans. Obesity (Silver Spring) 21(7), 1370–1379 (2013).
   Google Scholar
• Pattyn N, Cornelissen VA, Eshghi SR, Vanhees L. The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: a meta-analysis of controlled trials. Sports Med. 43(2), 121–133 (2013). • Systematic review and meta-analysis evaluating the effect of exercise on cardiovascular risk factors.
   Google Scholar
• Jane ML, Ho CC, Chen SC, Huang YC, Lai CH, Liaw YP. A simple method for increasing high-density lipoprotein cholesterol levels: a pilot study of combination aerobic and resistance exercise training. Int. J. Sport Nutr. Exerc. Metab. Accession number: 23307435 (2012) (Epub ahead of print).
   Google Scholar
• Fenske W, Parker J, Bloom R. Pharmacotherapy for obesity. Expert Rev. Endocrinol. Metab. 6(4), 563–577 (2011).
   Google Scholar
• Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int. J. Obes. Relat. Metab. Disord. 25(11), 1713–1721 (2001).
   Google Scholar
• James W, Caterson I, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363(10), 905–917 (2010).
   Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533–571 (2011).
   Google Scholar
• Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br. J. Clin. Pharmacol. 68(6), 861–874 (2009).
   Google Scholar
• Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Silbutramine Study Group. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am. Heart J. 142(3), 489–497 (2001).
   Google Scholar
• Sonnenberg G, Matfin G, Reinhardt R. Drug treatments for obesity: where are we heading and how do we get there? Br. J. Diabet. Vasc. Dis. 7(3), 111–118 (2007).
   Google Scholar
• Sjostrom L, Narbro K, Sjostrom CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357(8), 741–752 (2007).
   Google Scholar
• Le Roux CW, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann. Surg. 246(5), 780–785 (2007).
   Google Scholar
• Vincent RP, Le Roux CW. The satiety hormone peptide YY as a regulator of appetite. J. Clin. Pathol. 61(5), 548–552 (2008).
   Google Scholar
• Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch. Surg. 138(4), 389–396 (2003).
   Google Scholar
• Stępieę M, Wlazeł RN, Paradowski M et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study. Arch. Med. Sci. 8(3), 431–436 (2012).
   Google Scholar
• Stepien M, Rosniak-Bak K, Paradowski M et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med. Sci. Monit. 17(11), PR13–PR18 (2011).
   Google Scholar
• Yang HY, Tae J, Seo YW et al. Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity. Eur. J. Med. Chem. 63, 558–569 (2013).
   Google Scholar
• Stevanato J, Bertolla RP, Barradas V, Spaine DM, Cedenho AP, Ortiz V. Semen processing by density gradient centrifugation does not improve sperm apoptotic deoxyribonucleic acid fragmentation rates. Fertil. Steril. 90(3), 889–890 (2008).
   Google Scholar
• Blackett P, Tryggestad J, Krishnan S et al. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J. Clin. Lipidol. 7(2), 132–139 (2013).
   Google Scholar
• Nakou ES, Filippatos TD, Georgoula M et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr. Med. Res. Opin. 24(7), 1919–1929 (2008).
   Google Scholar
• Bryson A, De La Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br. J. Clin. Pharmacol. 67(3), 309–315 (2009).
   Google Scholar
• US FDA. FDA approves Belviq to treat some overweight or obese adults (2012). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm
   Google Scholar
• US FDA. FDA approves weight-management drug Qsymia (2012). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm
   Google Scholar
• Higgins GA, Sellers EM, Fletcher PJ. From obesity to substance abuse: therapeutic opportunities for 5-HT receptor agonists. Trends Pharmacol. Sci. 34(10), 560–570 (2013).
   Google Scholar
• Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 587(Pt 1), 49–60 (2009).
   Google Scholar
• Cone RD. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 8(5), 571–578 (2005).
   Google Scholar
• Higgins GA, Silenieks LB, Lau W et al. Evaluation of chemically diverse 5-HT(2)c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. Psychopharmacology (Berl.) 226(3), 475–490 (2013).
   Google Scholar
• Somerville EM, Horwood JM, Lee MD, Kennett GA, Clifton PG. 5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur. J. Neurosci. 25(10), 3115–3124 (2007).
   Google Scholar
• Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des. Devel. Ther. 5, 1–7 (2010).
   Google Scholar
• Smith BM, Smith JM, Tsai JH et al. Discovery and structureactivity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J. Med. Chem. 51(2), 305–313 (2008).
   Google Scholar
• Venkatesan A. Arena withdraws lorcaserin diet drug application in Europe. Reuters Health Information (2013).www.medscape.com/viewarticle/803585
   Google Scholar
• Martin CK, Redman LM, Zhang J et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J. Clin. Endocrinol. Metab. 96(3), 837–845 (2011).
   Google Scholar
• Fidler MC, Sanchez M, Raether B et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 96(10), 3067–3077 (2011). •• Recent 1-year randomized trial showing the effects of lorcaserin on weight loss in obese and overweight adults.
   Google Scholar
• Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol. Biochem. Behav. 97(1), 63–83 (2010).
   Google Scholar
• Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) +bupropion SR combination therapy for the treatment of obesity: ‘a new kid on the block’? Ann. Med. 43(4), 249–258 (2011).
   Google Scholar
• Allison DB, Gadde KM, Garvey WT et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20(2), 330–342 (2012). •• Recent randomized controlled trial showing the effects of the phentermine/topiramate combination on weight loss in obese and overweight adults.
   Google Scholar
• Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet 377(9774), 1341–1352 (2011).
   Google Scholar
• Garvey WT, Ryan DH, Look M et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, Phase 3 extension study. Am. J. Clin. Nutr. 95(2), 297–308 (2012).
   Google Scholar
• Fleming JW, Mcclendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/topiramate. Ann. Pharmacother. 47(7–8), 1007–1016 (2013).
   Google Scholar
• Contrave. Orexigen and FDA identify a clear and feasible path to approval for contrave (2011). www.drugs.com/nda/contrave_110920.html
   Google Scholar
• Apovian CM, Aronne L, Rubino D et al. A randomized, Phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 21(5), 935–943 (2013). •• Recent randomized trial showing effects of contrave on weight and weight-related risk factors in overweight and obese subjects.
   Google Scholar
• Bays HE. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev. Cardiovasc. Ther. 9(3), 265–277 (2011).
   Google Scholar
• Thatte U. NS-2330 (Neurosearch). Curr. Opin. Investig. Drugs 2(11), 1592–1594 (2001).
   Google Scholar
• Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 35(7), 1464–1476 (2010).
   Google Scholar
• Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372(9653), 1906–1913 (2008). •• Randomized, double-blind, placebo-controlled trial reporting promising effects of tesofensine on weight loss in obese subjects.
   Google Scholar
• Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 132(6), 2239–2252 (2007).
   Google Scholar
• Mastinu A, Pira M, Pani L, Pinna GA, Lazzari P. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. Behav. Brain Res. 234(2), 192–204 (2012).
   Google Scholar
• Mastinu A, Pira M, Pinna GA et al. NESS06SM reduces body weight with an improved profile relative to SR141716A. Pharmacol. Res. 74, 94–108 (2013).
   Google Scholar
• Gallwitz B. Anorexigenic effects of GLP-1 and its analogues. Handb. Exp. Pharmacol. 209, 185–207 (2012).
   Google Scholar
• Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin. Investig. Drugs 18(10), 1495–1503 (2009).
   Google Scholar
• Rizzo M, Nikolic D, Banach M et al. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives. Clin. Lipidol. 8, 173–181 (2013).
   Google Scholar
• Field BC, Chaudhri OB, Bloom SR. Obesity treatment: novel peripheral targets. Br. J. Clin. Pharmacol. 68(6), 830–843 (2009).
   Google Scholar
• Le Stunff H, Coant N, Migrenne S, Magnan C. Targeting lipid sensing in the central nervous system: new therapy against the development of obesity and Type 2 diabetes. Expert Opin. Ther. Targets 17(5), 545–555 (2013).
   Google Scholar
• Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32(7), 1224–1230 (2009).
   Google Scholar
• Plutzky J, Garber A, Toft AD, Poulter NR. A meta-analysis demonstrates that liraglutide, a once daily human GLP-1analogue significantly reduces lipids and other markers of cardiovascular risk in Type 2 diabetes Diabetologia 52(Suppl. 1 ), S1–S550 (2009).
   Google Scholar
• Rizzo M, Perez-Martinez P, Nikolic D, Montalto G, Lopez-Miranda J. Emerging approaches for the treatment of hypertriglyceridemia. Expert Opin. Pharmacother. 14(14), 1869–1873 (2013).
   Google Scholar
• Hata T, Mera Y, Ishii Y et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J. Pharmacol. Exp. Ther. 336(3), 850–856 (2011).
   Google Scholar
• Swanson HI, Wada T, Xie W et al. Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab. Dispos. 41(1), 1–11 (2013).
   Google Scholar
• Zhang Y, Huang C. Targeting adipocyte apoptosis: a novel strategy for obesity therapy. Biochem. Biophys. Res. Commun. 417(1), 1–4 (2012).
   Google Scholar
• Liew CW, Boucher J, Cheong JK et al. Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance. Nat. Med. 19(2), 217–226 (2013).
   Google Scholar
• Yao Y, Li XB, Zhao W et al. Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism. Lipids Health Dis. 9, 49 (2010).
   Google Scholar
• Yang L, Chen JH, Lv J et al. Rice protein improves adiposity, body weight and reduces lipids level in rats through modification of triglyceride metabolism. Lipids Health Dis. 11, 24 (2012).
   Google Scholar
• Velasquez MT, Bhathena SJ. Role of dietary soy protein in obesity. Int. J. Med. Sci. 4(2), 72–82 (2007).
   Google Scholar
• Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am. J. Clin. Nutr. 76(6), 1191–1201 (2002).
   Google Scholar
• Song T, Lee SO, Murphy PA, Hendrich S. Soy protein with or without isoflavones, soy germ and soy germ extract, and daidzein lessen plasma cholesterol levels in golden Syrian hamsters. Exp. Biol. Med. (Maywood) 228(9), 1063–1068 (2003).
   Google Scholar
• Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J. Nutr. 129(3), 758S–767S (1999).
   Google Scholar
• Jang EH, Moon JS, Ko JH et al. Novel black soy peptides with antiobesity effects: activation of leptin-like signaling and AMP-activated protein kinase. Int. J. Obes. (Lond.) 32(7), 1161–1170 (2008).
   Google Scholar
• Sashidhara KV, Kumar M, Sonkar R, Singh BS, Khanna AK, Bhatia G. Indole-based fibrates as potential hypolipidemic and antiobesity agents. J. Med. Chem. 55(6), 2769–2779 (2012).
   Google Scholar
• Cotrim BA, Joglar J, Rojas MJ et al. Unsaturated fatty alcohol derivatives of olive oil phenolic compounds with potential low-density lipoprotein (LDL) antioxidant and antiobesity properties. J. Agric. Food Chem. 60(4), 1067–1074 (2012).
   Google Scholar
• Overton HA, Babbs AJ, Doel SM et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3(3), 167–175 (2006).
   Google Scholar
• Ahn TG, Yang G, Lee HM et al. Molecular mechanisms underlying the anti-obesity potential of prunetin, an O-methylated isoflavone. Biochem. Pharmacol. 85(10), 1525–1533 (2013).
   Google Scholar